Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Facial changes related to brachycephaly in Cavalier King Charles Spaniels with Chiari-like malformation associated pain and secondary syringomyelia.

Knowler SP, Dumas E, Spiteri M, McFadyen AK, Stringer F, Wells K, Rusbridge C.

J Vet Intern Med. 2019 Nov 5. doi: 10.1111/jvim.15632. [Epub ahead of print]

2.

Chia seed mucilage - a vegan thickener: isolation, tailoring viscoelasticity and rehydration.

Brütsch L, Stringer FJ, Kuster S, Windhab EJ, Fischer P.

Food Funct. 2019 Aug 14;10(8):4854-4860. doi: 10.1039/c8fo00173a.

PMID:
31328195
3.

Changes in root-exudate-induced respiration reveal a novel mechanism through which drought affects ecosystem carbon cycling.

de Vries FT, Williams A, Stringer F, Willcocks R, McEwing R, Langridge H, Straathof AL.

New Phytol. 2019 Oct;224(1):132-145. doi: 10.1111/nph.16001. Epub 2019 Jul 24.

4.

Clinical Application of Diagnostic Imaging of Chiari-Like Malformation and Syringomyelia.

Rusbridge C, Stringer F, Knowler SP.

Front Vet Sci. 2018 Nov 28;5:280. doi: 10.3389/fvets.2018.00280. eCollection 2018. Review.

5.

Long-term Trends in Antidiabetes Drug Usage in the U.S.: Real-world Evidence in Patients Newly Diagnosed With Type 2 Diabetes.

Montvida O, Shaw J, Atherton JJ, Stringer F, Paul SK.

Diabetes Care. 2018 Jan;41(1):69-78. doi: 10.2337/dc17-1414. Epub 2017 Nov 6.

PMID:
29109299
6.

Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.

Stringer F, DeJongh J, Enya K, Koumura E, Danhof M, Kaku K.

Diabetes Technol Ther. 2015 Mar;17(3):215-23. doi: 10.1089/dia.2014.0222. Epub 2014 Dec 22.

7.

A model-based approach to analyze the influence of UGT2B15 polymorphism driven pharmacokinetic differences on the pharmacodynamic response of the PPAR agonist sipoglitazar.

Stringer F, DeJongh J, Scott G, Danhof M.

J Clin Pharmacol. 2014 Apr;54(4):453-61. doi: 10.1002/jcph.227. Epub 2013 Nov 20.

PMID:
24214217
8.

Evaluation of the impact of UGT polymorphism on the pharmacokinetics and pharmacodynamics of the novel PPAR agonist sipoglitazar.

Stringer F, Ploeger BA, DeJongh J, Scott G, Urquhart R, Karim A, Danhof M.

J Clin Pharmacol. 2013 Mar;53(3):256-63. doi: 10.1177/0091270012447121. Epub 2013 Jan 24.

PMID:
23444281
9.

The effect of genetic polymorphisms in UGT2B15 on the pharmacokinetic profile of sipoglitazar, a novel anti-diabetic agent.

Stringer F, Scott G, Valbuena M, Kinley J, Nishihara M, Urquhart R.

Eur J Clin Pharmacol. 2013 Mar;69(3):423-30. doi: 10.1007/s00228-012-1382-7. Epub 2012 Sep 9.

PMID:
22960998
10.

The impact of pharmacogenomics research on drug development.

Liou SY, Stringer F, Hirayama M.

Drug Metab Pharmacokinet. 2012;27(1):2-8. Epub 2012 Jan 3. Review.

11.
12.

Supplemental Content

Loading ...
Support Center